There are several Humira biosimilars available in the U.S. The group is led by Amgen's Amjevita (adalimumab-atto), which debuted on the U.S. market in January 2023. Then, in the span of a few days in July 2023 came a flurry of biosimilar launches, including Celltrion's Yuflyma (adalimumab-aaty), Sandoz's Hyrimoz (adalimumab-adaz), Boehringer Ingelheim's Cyltezo (adalimumab-adbm) and Organon's and Samsung Bioepis' Hadlima (adalimumab-bwwd). Most notable of these is Cyltezo, which also bears the FDA's interchangeability designation, meaning it has "no clinically meaningful differences" from Humira. Because of this designation, Cyltezo can also be given in place of the branded reference product without needing to change the prescription. The makers of these biosimilars have offered steep discounts on their products in an effort to sway buyers away from AbbVie.